Menter, A., A. Blauvelt, B. Strober, M. Colombo, R. Kisa, S. Kundu, S. Banerjee, and C. Leonardi. “Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s72, doi:10.25251/skin.4.supp.72.